Doctors have published a correspondence post warning that untested COVID-19 treatments might do more damage than good.
A group of physicians has actually released a correspondence article in the American Journal of Respiratory Cell and Molecular Biology warning that novel techniques to dealing with COVID-19 may do more damage than good.
The team, from the Department of Pulmonary and Crucial Care Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, argues that physicians must depend on attempted and tested, evidence-based intensive care practices instead of novel therapies.
The rapid development and growth of Sars-CoV-2, the infection that triggers COVID-19, has had an extraordinary result on social and cultural practices across the world.
It has also had a considerable influence on the medical staff and other health employees who are treating individuals who are significantly ill with COVID-19 Public health systems are under pressure due to the unexpected increase in patients needing intensive care.
Scientist and clinicians have been striving to understand the infection so that they can identify the most effective treatments and treatments to help save lives and alleviate the pressure on intensive care systems.
The group from Northwestern University has observed an increase in the use of untested therapies and treatments and those where scant proof or rationale for their efficiency exists.
The authors keep in mind that COVID-19 does not perfectly match some meanings of other Intense Breathing Distress Syndromes (ARDS), such as viral pneumonia. As a repercussion, COVID-19 has received a classification as a version of an ARDS.
The authors argue that this designation has motivated some doctors to utilize unique treatments instead of basic ARDS treatments when treating COVID-19
The authors believe this is an error and note that ARDS is a syndrome, and, as such, is heterogeneous. This implies it can provide in varied ways.
The authors concur that basic ARDS therapies are effecti